Can a new drug help sepsis patients with weak immune systems?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 years or older at the time of informed consent 2. Admitted to the ICU with a diagnosis of sepsis as defined by Sepsis-3 criteria: life-threatening organ dysfunction caused by a dysregulated host response to infection, operationalized as a Sequential Organ Failure Assessment (SOFA) score increase of 2 or more points 3. Documented persistent lymphopenia defined as ALC \<1,000 cells/µL on at least two consecutive measurements within 72 hours of sepsis diagnosis (measurements must be separated by at least 12 hours) 4. Prior initiation of appropriate antimicrobial therapy per institutional guidelines 5. Ability to obtain written informed consent from the participant or legally authorized representative 6. Agreement to practice effective contraception for female participants of child-bearing potential and non-sterile males (for up to 7 months after completion of therapy) Exclusion Criteria: 1. Hematologic malignancies including leukemia, lymphoma, and myelodysplastic syndromes 2. Prior CAR-T cell therapy or hematopoietic stem cell transplant (HSCT) within 3 months of screening 3. Active cytokine release syndrome (CRS) at screening 4. Current or recent (within 7 days) use of colony stimulating factors (G-CSF, GM-CSF) 5. Lymphopenia attributable to chemotherapy, radiation therapy, or immunosuppressive medications administered within 30 days prior to screening 6. High-dose immunosuppressive therapy (\>0.5 mg/kg prednisone equivalent daily), excluding physiologic replacement and stress-dose hydrocortisone for septic shock 7. Life expectancy less than 24 hours as assessed by the treating physician 8. Active uncontrolled bleeding requiring \>2 units of packed red blood cells in the preceding 24 hours 9. Known HIV infection with CD4 count \<350 cells/µL and detectable viral load 10. Known active viral hepatitis (hepatitis B or C with detectable viral load) 11. Advanced dementia or other conditions precluding meaningful participation 12. Known hypersensitivity to any component of the investigational products 13. Participation in another interventional trial with an investigational immunomodulatory agent within 30 days prior to screening 14. Pregnant or breastfeeding